
    
      The IMC-F106C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable
      tumors which include select Advanced Solid Tumors and will be conducted in two phases.

        1. Phase 1: To identify the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 dose
           (RP2D) of IMC-F106C as a single agent (Arm A) and administered in combination with
           Checkpoint Inhibitors (Arm B).

        2. Phase 2: To assess the preliminary anti-tumor activity of IMC-F106C in up to 4
           indications, as a single agent administration.
    
  